Previous close | 1,044.50 |
Open | 1,040.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 1,032.00 - 1,045.95 |
52-week range | 850.00 - 1,083.00 |
Volume | |
Avg. volume | 1,741,603 |
Market cap | 834.147B |
Beta (5Y monthly) | 0.46 |
PE ratio (TTM) | 33.54 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 5.00 (0.48%) |
Ex-dividend date | 08 Aug 2022 |
1y target est | N/A |
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).